RET
Read More about this categoryShow Less
RET (REarranged during Transfection) is a receptor protein tyrosine kinase, which activates multiple signal transduction pathways. RET protein is composed of three domains: an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. The RET receptor tyrosine kinase (RTK) regulates key aspects of cellular proliferation and survival by regulating the activity of the mitogen- activated protein kinase (MAPK) and PI3K/Akt signaling pathways. RET also interacts directly with other kinases such as the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) and the focal adhesion kinase (FAK). Furthermore, BRAF and p38MAPK are downstream targets of RET. Kinase inhibitors that simultaneously inhibit RET and its downstream targets.
RET tyrosine kinase receptor presents an attractive therapeutic target for the treatment of certain cancer subsets. Deregulated RET activity has been identified as a causative factor in the development, progression and response to therapy of thyroid carcinoma. Elevated RET expression has been associated with the development of endocrine resistance in human breast cancer.
Products Related to RET(32)
- GC65354EnbezotinibCAS: 2359649-81-1Purity: >99.00%
Enbezotinib, ein Inhibitor von RET, kann die RET-Autophosphorylierung hemmen. Enbezotinib kann zur Krebsforschung eingesetzt werden.
- GC81325VEGFR2-IN-84CAS: 861877-12-5Purity: >98%
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC65354 | Enbezotinib | 2359649-81-1 | >99.00% | |
Enbezotinib, ein Inhibitor von RET, kann die RET-Autophosphorylierung hemmen. Enbezotinib kann zur Krebsforschung eingesetzt werden. | ||||
| GC67917 | RET-IN-7 | 2763386-05-4 | >98% | |
| GC68396 | Vepafestinib | 2129515-96-2 | >98.00% | |
| GC68623 | AD57 | 1093380-42-7 | >98.00% | |
AD57 ist ein Mehrfachkinase-Inhibitor mit oralen Aktivitäten, der die Aktivität von RET, BRAF, S6K und Src hemmt, aber die Aktivität von mTOR deutlich schwächt. | ||||
| GC68812 | BT44 | 924759-42-2 | >99.00% | |
BT44 ist ein selektiver RET-Aktivator. BT44 kann die Blut-Hirn-Schranke durchdringen und eignet sich zur Erforschung neurodegenerativer Erkrankungen und Diabetes. | ||||
| GC73196 | RET-IN-21 | 2414373-42-3 | >97.00% | |
RET-IN-21 ist ein Inhibitor der Rezeptor Tyrosinkinase (RET), mit dem IC50 von 4,4 μM, der antitumorale Aktivität hat. | ||||
| GC79484 | APS03118 | 2598870-24-5 | >98.50% | |
APS03118 is an orally active, potent and selective rearranged during transfection ( RET ) inhibitor. | ||||
| GC81325 | VEGFR2-IN-84 | 861877-12-5 | >98% | |
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. | ||||
